Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Reduced exposure to darunavir and cobicistat in HIV-1-infected pregnant women receiving a darunavir/cobicistat-based regimen.

Crauwels HM, Osiyemi O, Zorrilla C, Bicer C, Brown K.

HIV Med. 2019 May;20(5):337-343. doi: 10.1111/hiv.12721. Epub 2019 Mar 14.

PMID:
30873741
2.

Impact of Splitting or Crushing on the Relative Bioavailability of the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen.

Brown K, Thomas D, McKenney K, Reeder M, Simonson RB, Bicer C, Nettles RE, Crauwels H.

Clin Pharmacol Drug Dev. 2019 May;8(4):541-548. doi: 10.1002/cpdd.632. Epub 2018 Dec 3.

PMID:
30508308
3.

Bioequivalence of the Once-Daily Single-Tablet Regimen of Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Compared to Combined Intake of the Separate Agents and the Effect of Food on Bioavailability.

Crauwels HM, Baugh B, Van Landuyt E, Vanveggel S, Hijzen A, Opsomer M.

Clin Pharmacol Drug Dev. 2019 May;8(4):480-491. doi: 10.1002/cpdd.628. Epub 2018 Nov 9.

PMID:
30412360
4.

Bioequivalence of a Fixed-Dose Combination Tablet of the Complete Two-Drug Regimen of Dolutegravir and Rilpivirine for Treatment of HIV-1 Infection.

Mehta R, Wolstenholme A, Di Lullo K, Fu C, Joshi S, Crauwels H, Givens N, Vanveggel S, Wynne B, Adkison K.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e00748-18. doi: 10.1128/AAC.00748-18. Print 2018 Sep.

5.

Pharmacokinetics, Antiviral Activity, and Safety of Rilpivirine in Pregnant Women with HIV-1 Infection: Results of a Phase 3b, Multicenter, Open-Label Study.

Osiyemi O, Yasin S, Zorrilla C, Bicer C, Hillewaert V, Brown K, Crauwels HM.

Infect Dis Ther. 2018 Mar;7(1):147-159. doi: 10.1007/s40121-017-0184-8. Epub 2018 Jan 15.

6.

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.

Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, Eron JJ, Yazdanpanah Y, Podzamczer D, Lutz T, Angel JB, Richmond GJ, Clotet B, Gutierrez F, Sloan L, Clair MS, Murray M, Ford SL, Mrus J, Patel P, Crauwels H, Griffith SK, Sutton KC, Dorey D, Smith KY, Williams PE, Spreen WR.

Lancet. 2017 Sep 23;390(10101):1499-1510. doi: 10.1016/S0140-6736(17)31917-7. Epub 2017 Jul 24.

PMID:
28750935
7.

Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial.

Arathoon E, Bhorat A, Silaghi R, Crauwels H, Lavreys L, Tambuyzer L, Van Baelen B, Vanveggel S, Opsomer M.

SAGE Open Med. 2017 Jan 18;5:2050312116686482. doi: 10.1177/2050312116686482. eCollection 2017.

8.

Rilpivirine as a Treatment for HIV-infected Antiretroviral-naïve Adolescents: Week 48 Safety, Efficacy, Virology and Pharmacokinetics.

Lombaard J, Bunupuradah T, Flynn PM, Ramapuram J, Ssali F, Crauwels H, Hoogstoel A, Van Eygen V, Stevens M.

Pediatr Infect Dis J. 2016 Nov;35(11):1215-1221.

PMID:
27294305
9.

Evaluation of Concomitant Antiretrovirals and CYP2C9/CYP2C19 Polymorphisms on the Pharmacokinetics of Etravirine.

Green B, Crauwels H, Kakuda TN, Vanveggel S, Brochot A.

Clin Pharmacokinet. 2017 May;56(5):525-536. doi: 10.1007/s40262-016-0454-8.

PMID:
27665573
10.

Pharmacokinetics of once-daily darunavir/ritonavir in HIV-1-infected pregnant women.

Crauwels HM, Kakuda TN, Ryan B, Zorrilla C, Osiyemi OO, Yasin S, Brown K, Verboven P, Hillewaert V, Baugh B.

HIV Med. 2016 Oct;17(9):643-52. doi: 10.1111/hiv.12366. Epub 2016 May 17. Erratum in: HIV Med. 2019 Aug;20(7):496-499.

11.

Pharmacokinetics of Total and Unbound Etravirine in HIV-1-Infected Pregnant Women.

Ramgopal M, Osiyemi O, Zorrilla C, Crauwels HM, Ryan R, Brown K, Hillewaert V, Baugh B.

J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):268-274.

PMID:
27159225
12.

Pharmacokinetic profile after multiple deltoid or gluteal intramuscular injections of paliperidone palmitate in patients with schizophrenia.

Rossenu S, Cleton A, Hough D, Crauwels H, Vandebosch A, Berwaerts J, Eerdekens M, Herben V, De Meulder M, Remmerie B, Francetic I.

Clin Pharmacol Drug Dev. 2015 Jul;4(4):270-8. doi: 10.1002/cpdd.144. Epub 2014 Aug 28.

PMID:
27136907
13.

Formulation and pharmacology of long-acting rilpivirine.

Williams PE, Crauwels HM, Basstanie ED.

Curr Opin HIV AIDS. 2015 Jul;10(4):233-8. doi: 10.1097/COH.0000000000000164. Review.

PMID:
26049947
14.

Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteers.

Verloes R, Deleu S, Niemeijer N, Crauwels H, Meyvisch P, Williams P.

HIV Med. 2015 Sep;16(8):477-84. doi: 10.1111/hiv.12247. Epub 2015 May 18.

15.

Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: A randomized, two-way crossover trial.

Kakuda TN, Leopold L, Nijs S, Vandevoorde A, Crauwels HM, Bertelsen KM, Stevens M, Witek J, van Delft Y, Tomaka F, Hoetelmans RM.

J Clin Pharmacol. 2014 May;54(5):563-73. doi: 10.1002/jcph.245.

PMID:
25975423
16.

Darunavir/cobicistat once daily for the treatment of HIV.

Kakuda TN, Crauwels H, Opsomer M, Tomaka F, van de Casteele T, Vanveggel S, Iterbeke K, de Smedt G.

Expert Rev Anti Infect Ther. 2015 Jun;13(6):691-704. doi: 10.1586/14787210.2015.1033400. Review.

PMID:
25962100
17.

Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults.

Spreen W, Williams P, Margolis D, Ford SL, Crauwels H, Lou Y, Gould E, Stevens M, Piscitelli S.

J Acquir Immune Defic Syndr. 2014 Dec 15;67(5):487-92. doi: 10.1097/QAI.0000000000000365.

PMID:
25473882
18.

Week 48 results of a Phase IV trial of etravirine with antiretrovirals other than darunavir/ritonavir in HIV-1-infected treatment-experienced adults.

Arathoon E, Bhorat A, Silaghi R, Crauwels H, Lavreys L, Tambuyzer L, Vanveggel S, Opsomer M.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19783. doi: 10.7448/IAS.17.4.19783. eCollection 2014.

19.

A single-dose, open-label, parallel, randomized, dose-proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophrenia.

Cleton A, Rossenu S, Crauwels H, Berwaerts J, Hough D, Gopal S, Eerdekens M, Vandebosch A, Remmerie B, De Meulder M, Rosso CM.

J Clin Pharmacol. 2014 Sep;54(9):1048-57. doi: 10.1002/jcph.295. Epub 2014 Apr 3.

PMID:
24676998
20.

The effect of rilpivirine on the pharmacokinetics of methadone in HIV-negative volunteers.

Crauwels HM, van Heeswijk RP, Vandevoorde A, Buelens A, Stevens M, Hoetelmans RM.

J Clin Pharmacol. 2014 Feb;54(2):133-40. doi: 10.1002/jcph.222. Epub 2013 Nov 23.

PMID:
24203510
21.

Lack of an effect of rilpivirine on the pharmacokinetics of ethinylestradiol and norethindrone in healthy volunteers.

Crauwels HM, van Heeswijk RP, Buelens A, Stevens M, Hoetelmans RM.

Int J Clin Pharmacol Ther. 2014 Feb;52(2):118-28. doi: 10.5414/CP201943.

PMID:
24161160
22.

Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744.

Ford SL, Gould E, Chen S, Margolis D, Spreen W, Crauwels H, Piscitelli S.

Antimicrob Agents Chemother. 2013 Nov;57(11):5472-7. doi: 10.1128/AAC.01235-13. Epub 2013 Aug 26.

23.

Impact of food and different meal types on the pharmacokinetics of rilpivirine.

Crauwels HM, van Heeswijk RP, Buelens A, Stevens M, Boven K, Hoetelmans RM.

J Clin Pharmacol. 2013 Aug;53(8):834-40. doi: 10.1002/jcph.107. Epub 2013 May 30.

PMID:
23720136
24.

Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine.

Crauwels H, van Heeswijk RP, Stevens M, Buelens A, Vanveggel S, Boven K, Hoetelmans R.

AIDS Rev. 2013 Apr-Jun;15(2):87-101. Review.

PMID:
23681436
25.

Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials.

Cohen CJ, Molina JM, Cassetti I, Chetchotisakd P, Lazzarin A, Orkin C, Rhame F, Stellbrink HJ, Li T, Crauwels H, Rimsky L, Vanveggel S, Williams P, Boven K; ECHO, THRIVE study groups.

AIDS. 2013 Mar 27;27(6):939-50. doi: 10.1097/QAD.0b013e32835cee6e.

PMID:
23211772
26.

Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE.

Hodder S, Arasteh K, De Wet J, Gathe J, Gold J, Kumar P, Mohapi L, Short W, Crauwels H, Vanveggel S, Boven K.

HIV Med. 2012 Aug;13(7):406-15. doi: 10.1111/j.1468-1293.2012.00991.x. Epub 2012 Mar 14.

27.

Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials.

Cohen CJ, Molina JM, Cahn P, Clotet B, Fourie J, Grinsztejn B, Wu H, Johnson MA, Saag M, Supparatpinyo K, Crauwels H, Lefebvre E, Rimsky LT, Vanveggel S, Williams P, Boven K; ECHO Study Group; THRIVE Study Group.

J Acquir Immune Defic Syndr. 2012 May 1;60(1):33-42. doi: 10.1097/QAI.0b013e31824d006e.

PMID:
22343174
28.

Pharmacokinetic parameters of once-daily rilpivirine following administration of efavirenz in healthy subjects.

Crauwels H, Vingerhoets J, Ryan R, Witek J, Anderson D.

Antivir Ther. 2012;17(3):439-46. doi: 10.3851/IMP1959. Epub 2011 Nov 9.

PMID:
22293086
29.

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.

Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, Supparatpinyo K, Walmsley S, Crauwels H, Rimsky LT, Vanveggel S, Boven K; ECHO study group.

Lancet. 2011 Jul 16;378(9787):238-46. doi: 10.1016/S0140-6736(11)60936-7.

PMID:
21763936
30.

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.

Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, Ruxrungtham K, Wu H, Zorrilla C, Crauwels H, Rimsky LT, Vanveggel S, Boven K; THRIVE study group.

Lancet. 2011 Jul 16;378(9787):229-37. doi: 10.1016/S0140-6736(11)60983-5.

PMID:
21763935
31.

Transcription profiles of aortic smooth muscle cells from atherosclerosis-prone and -resistant regions in young apolipoprotein E-deficient mice before plaque development.

Van Assche T, Hendrickx J, Crauwels HM, Guns PJ, Martinet W, Fransen P, Raes M, Bult H.

J Vasc Res. 2011;48(1):31-42. doi: 10.1159/000317398. Epub 2010 Jul 6.

32.

Drug interactions with new and investigational antiretrovirals.

Crauwels HM, Kakuda TN.

Clin Pharmacokinet. 2010;49(1):67-8; author reply 68-9. No abstract available.

PMID:
20020564
33.

The influence of hepatic impairment on the pharmacokinetics of paliperidone.

Boom S, Thyssen A, Crauwels H, Molz KH, Cleton A, Janssens L, Talluri K, Eerdekens M.

Int J Clin Pharmacol Ther. 2009 Oct;47(10):606-16.

PMID:
19825324
34.

Pharmacological characterization of nucleotide P2Y receptors on endothelial cells of the mouse aorta.

Guns PJ, Korda A, Crauwels HM, Van Assche T, Robaye B, Boeynaems JM, Bult H.

Br J Pharmacol. 2005 Sep;146(2):288-95.

35.

Plaque-associated endothelial dysfunction in apolipoprotein E-deficient mice on a regular diet. Effect of human apolipoprotein AI.

Crauwels HM, Van Hove CE, Holvoet P, Herman AG, Bult H.

Cardiovasc Res. 2003 Jul 1;59(1):189-99.

PMID:
12829190
36.

Heterogeneity in relaxation mechanisms in the carotid and the femoral artery of the mouse.

Crauwels HM, Van Hove CE, Herman AG, Bult H.

Eur J Pharmacol. 2000 Sep 22;404(3):341-51.

PMID:
10996599
37.

Supplemental Content

Loading ...
Support Center